176 related articles for article (PubMed ID: 24980826)
1. Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence.
Bifulco K; Votta G; Ingangi V; Di Carluccio G; Rea D; Losito S; Montuori N; Ragno P; Stoppelli MP; Arra C; Carriero MV
Oncotarget; 2014 Jun; 5(12):4154-69. PubMed ID: 24980826
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.
Minopoli M; Botti G; Gigantino V; Ragone C; Sarno S; Motti ML; Scognamiglio G; Greggi S; Scaffa C; Roca MS; Stoppelli MP; Ciliberto G; Losito NS; Carriero MV
J Exp Clin Cancer Res; 2019 Nov; 38(1):459. PubMed ID: 31703596
[TBL] [Abstract][Full Text] [Related]
3. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Ragone C; Minopoli M; Ingangi V; Botti G; Fratangelo F; Pessi A; Stoppelli MP; Ascierto PA; Ciliberto G; Motti ML; Carriero MV
J Exp Clin Cancer Res; 2017 Dec; 36(1):180. PubMed ID: 29216889
[TBL] [Abstract][Full Text] [Related]
4. Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR).
Resnati M; Pallavicini I; Daverio R; Sidenius N; Bonini P; Blasi F
J Immunol Methods; 2006 Jan; 308(1-2):192-202. PubMed ID: 16386755
[TBL] [Abstract][Full Text] [Related]
5. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
Lutz V; Reuning U; Krüger A; Luther T; von Steinburg SP; Graeff H; Schmitt M; Wilhelm OG; Magdolen V
Biol Chem; 2001 May; 382(5):789-98. PubMed ID: 11517932
[TBL] [Abstract][Full Text] [Related]
6. The cleavage of the urokinase receptor regulates its multiple functions.
Montuori N; Carriero MV; Salzano S; Rossi G; Ragno P
J Biol Chem; 2002 Dec; 277(49):46932-9. PubMed ID: 12297505
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Knör S; Sato S; Huber T; Morgenstern A; Bruchertseifer F; Schmitt M; Kessler H; Senekowitsch-Schmidtke R; Magdolen V; Seidl C
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):53-64. PubMed ID: 17891393
[TBL] [Abstract][Full Text] [Related]
8. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator.
Jo M; Thomas KS; Marozkina N; Amin TJ; Silva CM; Parsons SJ; Gonias SL
J Biol Chem; 2005 Apr; 280(17):17449-57. PubMed ID: 15728176
[TBL] [Abstract][Full Text] [Related]
9. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract][Full Text] [Related]
10. The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis.
Leduc D; Beaufort N; de Bentzmann S; Rousselle JC; Namane A; Chignard M; Pidard D
Infect Immun; 2007 Aug; 75(8):3848-58. PubMed ID: 17517866
[TBL] [Abstract][Full Text] [Related]
11. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.
de Paulis A; Montuori N; Prevete N; Fiorentino I; Rossi FW; Visconte V; Rossi G; Marone G; Ragno P
J Immunol; 2004 Nov; 173(9):5739-48. PubMed ID: 15494526
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
Sato S; Kopitz C; Grismayer B; Beaufort N; Reuning U; Schmitt M; Luther T; Kotzsch M; Krüger A; Magdolen V
Breast Cancer Res Treat; 2011 Jun; 127(3):649-57. PubMed ID: 20635136
[TBL] [Abstract][Full Text] [Related]
13. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
Tummalapalli P; Gondi CS; Dinh DH; Gujrati M; Rao JS
Int J Oncol; 2007 Jul; 31(1):5-17. PubMed ID: 17549400
[TBL] [Abstract][Full Text] [Related]
14. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Schiller HB; Szekeres A; Binder BR; Stockinger H; Leksa V
Mol Biol Cell; 2009 Feb; 20(3):745-56. PubMed ID: 19037107
[TBL] [Abstract][Full Text] [Related]
15. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
16. The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.
Tucker TA; Dean C; Komissarov AA; Koenig K; Mazar AP; Pendurthi U; Allen T; Idell S
Am J Respir Cell Mol Biol; 2010 Jun; 42(6):685-96. PubMed ID: 19635932
[TBL] [Abstract][Full Text] [Related]
17. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
18. Differential roles of uPAR in peritoneal ovarian carcinomatosis.
Al-Hassan NN; Behzadian A; Caldwell R; Ivanova VS; Syed V; Motamed K; Said NA
Neoplasia; 2012 Apr; 14(4):259-70. PubMed ID: 22577342
[TBL] [Abstract][Full Text] [Related]
19. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
[TBL] [Abstract][Full Text] [Related]
20. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
Jo M; Takimoto S; Montel V; Gonias SL
Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
